Cytotoxicity of targeted PLGA nanoparticles: a systematic review. Issue 16 (3rd March 2021)

• Record Type: Journal Article
• Authors: Chiu, Hock Ing; Samad, Nozlena Abdul; Fang, Lizhen; Lim, Vuanghao
• Is Part Of: RSC advances. Volume 11:Issue 16(2021)
• Page Start: 9433
• Page End: 9449
• Publication Date: 2021-03-03
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1039/d1ra00074h
• Languages: English
• ISSNs: 2046-2069

Abstract

Abstract : Targeted drug delivery systems using PLGA as a nanocarrier for anti-cancer agents to improve efficacy and reduce toxicity in normal cells. Abstract : Recent advances in nanotechnology have contributed tremendously to the development and revolutionizing of drug delivery systems in the field of nanomedicine. In particular, targeting nanoparticles based on biodegradable poly(lactic- co -glycolic acid) (PLGA) polymers have gained much interest. However, PLGA nanoparticles remain of concern for their effectiveness against cancer cells and their toxicity to normal cells. The aim of this systematic review is to identify a promising targeting PLGA nanoformulation based on the comparison study of their cytotoxicity potency in different cell lines. A literature search was conducted through the databases of Google Scholar, PubMed, ScienceDirect, Scopus and SpringerLink. The sources studied were published between 2009 and 2019, and a variety of keywords were utilized. In total, 81 manuscripts that met the inclusion and exclusion criteria were selected for analysis based on their cytotoxicity, size, zeta potential, year of publication, type of ligand, active compounds and cell line used. The half maximal inhibitory concentration (IC50 ) for cytotoxicity was the main measurement in this data extraction, and the SI units were standardized to μg mL −1 for a better view of comparison. This systematic review also identified that cytotoxicity potency was inversely proportional to nanoparticle size. The PLGA nanoparticles predominantly exhibited a size of less than 300 nm and absolute zeta potential ∼20 mV. In conclusion, more comprehensive and critical appraisals of pharmacokinetic, pharmacokinetic, toxicokinetic, in vivo and in vitro tests are required for the investigation of the full value of targeting PLGA nanoparticles for cancer treatment.